Torren Management
PTCT icon

Torren Management’s PTC Therapeutics PTCT Stock Holding History

Torren Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$518 Hold
8
– – ﹤0.01% 848
2026
Q2 		$653 Hold
8
– – ﹤0.01% 825
2026
Q1 		$545 Hold
8
– – ﹤0.01% 867
2025
Q4 		$608 Buy
+8
New +$581 ﹤0.01% 1298

Other funds holding PTCT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Natixis
Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Torren Management's PTCT Position: Q3 2026 in Review

Torren Management held its PTC Therapeutics (PTCT) position steady in Q3 2026 at 8 shares worth $518. The position accounts for ﹤0.01% of the portfolio, ranked #848.

Torren Management first reported a position in PTCT in Q4 2025 and has held it in 4 quarters since. The position peaked at $653 in Q2 2026. 140 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • Torren Management held 8 shares of PTC Therapeutics worth $518 as of Q3 2026.
  • Torren Management left its PTC Therapeutics share count unchanged in Q3 2026.
  • PTC Therapeutics made up ﹤0.01% of Torren Management's portfolio in Q3 2026, its #848 holding.
  • Torren Management first reported a position in PTC Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Torren Management's PTC Therapeutics position peaked at $653 in Q2 2026.
  • 140 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on Torren Management's 13F filing for Q3 2026, filed 29 Oct 2026.